ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
102.888
+0.128 (+0.12%)
As of 11:49AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close102.760
Open102.100
Bid102.390 x 800
Ask102.680 x 1800
Day's Range100.450 - 102.990
52 Week Range70.760 - 153.990
Volume228,057
Avg. Volume764,479
Market Cap10.343B
Beta3.25
PE Ratio (TTM)N/A
EPS (TTM)-5.580
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est148.00
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ALNY totaled $674 million.

  • How Analysts Are Rating Puma Biotechnology in July
    Market Realist8 days ago

    How Analysts Are Rating Puma Biotechnology in July

    The positive recommendation from CHMP comes after a reexamination of negative recommendations at the meeting for the MAA on February 23. On July 5, the company had a consensus 12-month target price of $94.17, which represents a 60.29% return on investment over the next 12 months. On July 5, Incyte had a consensus 12-month target price of $83.71, which represents an 18.65% return on investment over the next 12 months.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit10 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Benzinga11 days ago

    Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run

    Arbutus Biopharma Corp (NASDAQ: ABUS ) stock has gained 80 percent since the turn of the year, and B. Riley FBR dropped its bullish stance Friday in the wake of the rally.   The Analyst B. Riley FBR's ...

  • Why This Biotech Company 'Dominates' Its Rival In Drug Study
    Investor's Business Daily12 days ago

    Why This Biotech Company 'Dominates' Its Rival In Drug Study

    Alnylam seemingly outperformed rival Ionis in tests of drugs to treat a progressive rare disease, an analyst said Thursday. Both biotech companies are making treatments for a condition known as hereditary ATTR amyloidosis.

  • Business Wire13 days ago

    Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the pivotal study results from the APOLLO Phase 3 trial of patisiran were published online today in The New England Journal of Medicine (NEJM). The study showed that patisiran improved measures of polyneuropathy, quality of life, activities of daily living, ambulation, nutritional status, and autonomic symptoms relative to placebo in patients with hereditary transthyretin-mediated (hATTR) amyloidosis, an inevitably progressive and generally fatal disease. Further, the frequency and severity of adverse events (AEs) were similar in patients receiving patisiran and placebo, with the exception of peripheral edema and infusion-related events which were higher in patisiran-treated patients and generally mild to moderate in severity.

  • Medicines Company's Inclisiran Studies to Continue Unmodified
    Zacks19 days ago

    Medicines Company's Inclisiran Studies to Continue Unmodified

    The Medicines Company (MDCO) announces that Independent Data Monitoring Committee has recommended that the ongoing phase III studies of its candidate, inclisiran, will continue without modification.

  • GlobeNewswire20 days ago

    Report: Developing Opportunities within Valvoline, Parker Drilling, Dean Foods, BioPharmX, Hasbro, and Alnylam Pharmaceuticals — Future Expectations, Projections Moving into 2018

    NEW YORK, June 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Valvoline ...

  • Business Wire26 days ago

    Alnylam to Host Fifth Annual “RNAi Roundtable” Webcast Series

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 5th annual series of “RNAi Roundtable” webcasts this summer. The 2018 series will offer a range of presentations from Alnylam scientists, clinical collaborators, and patients or patient advocates, who will review recent progress in many of the Company’s late-stage pipeline programs and platform.

  • Caladrius Biosciences’ Stock Price Rose 67% on June 19
    Market Realist27 days ago

    Caladrius Biosciences’ Stock Price Rose 67% on June 19

    On June 19, Caladrius Biosciences’ stock price rose 67.3% and reached $6.61 from the previous close of $3.95 on June 18.

  • Business Wire27 days ago

    Alnylam Expands Senior Leadership Team with Two Key Appointments

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today the appointments of two accomplished biotech executives, Masako Nakamura as Senior Vice President, Head of Asia, and Jing L. Marantz, M.D., Ph.D., as Senior Vice President, Head of Medical Affairs. "We are pleased to have Masako and Jing join us at an exciting crossroads in Alnylam’s journey from an R&D to a commercial organization.

  • Business Wirelast month

    Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology

    Alnylam Pharmaceuticals, Inc.  , the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR amyloidosis, will be presented at the 4th Congress of the European Academy of Neurology , being held June 16-19, 2018 in Lisbon, Portugal.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Intercept Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / June 13, 2018 / U.S. markets were relatively quiet following the summit between President Donald Trump and North Korean leader Kim Jong Un in Singapore. The Dow Jones Industrial ...

  • Business Wirelast month

    Over 700 Alnylam Employees Volunteer at the Company’s 4th Annual “Helping Hands” Community Service Day

    Alnylam Pharmaceuticals, Inc.  , the leading RNAi therapeutics company, today kicked off its fourth annual company-wide “Helping Hands” Community Service Day benefiting 23 organizations, including 16 organizations in the Greater Boston area and seven organizations in Western Europe.

  • ACCESSWIRElast month

    Wired News – Alnylam Pharma Presented New Encouraging Results from Phase-1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type-1

    LONDON, UK / ACCESSWIRE / June 12, 2018 / If you want access to our free research report on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALNY as the Company’s latest news hit the wire. On June 08, 2018, the Company presented updated positive results from its Phase-1/2 study assessing lumasiran for the treatment of Primary Hyperoxaluria Type-1 (PH1) at the OxalEurope, European Hyperoxaluria Consortium in Naples, Italy. Active-Investors.com is currently working on the research report for Cleveland BioLabs, Inc. (NASDAQ: CBLI), which also belongs to the Healthcare sector as the Company Alnylam Pharma.

  • Alnylam Reports Positive Data on Lumasiran in Renal Disease
    Zackslast month

    Alnylam Reports Positive Data on Lumasiran in Renal Disease

    Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients.

  • ACCESSWIRElast month

    Stock Performance Review on Alder Biopharma and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want a free Stock Review on ALDR sign up now at www.wallstequities.com/registration. Gains were broad based as seven out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and Altimmune Inc. (NASDAQ: ALT).

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Business Wirelast month

    Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase (GO) for the treatment of Primary Hyperoxaluria Type 1 (PH1). Results were presented at the OxalEurope, European Hyperoxaluria Consortium, taking place on June 8, 2018 in Naples, Italy. Part B is a randomized (3:1 drug:placebo), single-blind, placebo-controlled evaluation of lumasiran in patients with PH1.

  • 3 Top Biotech Stocks to Buy in June
    Motley Foollast month

    3 Top Biotech Stocks to Buy in June

    The cure for your portfolio's ills might be found in these three mid-cap biotech stocks.

  • Business Wirelast month

    Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALN-TTRsc02, an investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis. “We are very pleased to have received Orphan Drug Designation from the FDA for ALN-TTRsc02, which we believe has the potential to become a meaningful treatment option for people living with ATTR amyloidosis, a progressive, debilitating, and often fatal disease,” said Rena Denoncourt, Program Leader, ALN-TTRsc02 Program at Alnylam. The FDA Orphan Drug Designation Program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S.

  • Why Is Alnylam (ALNY) Up 12.6% Since Its Last Earnings Report?
    Zackslast month

    Why Is Alnylam (ALNY) Up 12.6% Since Its Last Earnings Report?

    Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam Pharmaceuticals, Inc.
    Motley Foollast month

    Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam Pharmaceuticals, Inc.

    Which stock wins in a battle between these two clinical-stage biotechs with regulatory approvals potentially just around the corner?

  • The Upside Potential in Editas Medicine Stock
    Market Realist2 months ago

    The Upside Potential in Editas Medicine Stock

    Editas has key collaboration agreements with Juno Therapeutics and Allergan Pharmaceuticals. Of the nine analysts covering Editas Medicine in May, five have given the stock “buy” or higher ratings, three have given it “hold” ratings, and one has given it a “strong sell” rating. The mean rating for the stock is 2.67, and its target price is $45.2, implying an upside potential of 23.4% over its closing price of $36.63 on May 24.

  • Business Wire2 months ago

    Alnylam to Webcast Presentations at Upcoming June Investor Conferences

    Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: